Drug intelligence / Profile preview

JoyRise

Development stage: Preclinical
Lead developer: Joyrise
Modality: Small Molecules
Administration: Oral

Overview

JoyRise is a multi-ingredient dietary supplement formulated as a recovery powder to alleviate the negative aftereffects of alcohol consumption, such as hangovers, cognitive impairment, and anxiety. The product is designed to be consumed orally after drinking. Its formulation typically includes dihydromyricetin (DHM), L-theanine, vitamins, and electrolytes, which work together to support alcohol metabolism and mitigate neurological symptoms. A clinical study (NCT06575972) has been conducted to evaluate its efficacy in reducing hangover severity and improving cognitive function in adults aged 35-54.

Brand names: JoyRise
Other names: JoyRise Recovery Powder

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)ADH (Alcohol dehydrogenase family)ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)

Beyond the preview

Go deeper on JoyRise.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JoyRise.

Explore the full profile